CJC-1295 no DAC 2026: Cost, Samples & Access for the Short-Acting GHRH Peptide
CJC-1295 no DAC — also called Modified GRF (1-29) — is a 30-amino-acid GHRH analog with four amino acid substitutions that resist enzymatic degradation but no albumin-binding tail. Half-life is roughly 30 minutes. The clinical effect is a discrete GH pulse rather than the sustained elevation produced by CJC-1295 with DAC.
Functionally, CJC-1295 no DAC and sermorelin are very similar — both produce pulse-pattern GH stimulation, both are dosed daily, both are typically paired with a GHRP like ipamorelin. The choice between them is often clinician preference and pharmacy availability rather than a meaningful clinical distinction.
Like the rest of the CJC-1295 family, this variant was removed from the FDA Cat-2 list in September 2024 and remains in regulatory limbo pending PCAC review. 503A compounding continues.
- 10 programs ranked
- Editor-reviewed
- Reader-verified
- Updated weekly
What's actually available: CJC-1295 no DAC (Modified GRF 1-29) samples in 2026
Three paths for people typing “cjc-1295 no dac (modified grf 1-29)samples” — what they actually mean, typical cost, and who each path fits.
| Path | What it actually is | Typical cost | Best for |
|---|---|---|---|
| Telehealth peptide subscription | Hone, Eden, Henry Meds — bundle of consult + CJC-1295 no DAC + ipamorelin. | $99-229 / month all-in | Patients wanting GHRH + GHRP combo with pulse-pattern dosing |
| Peptide clinic (Marek / Defy / LIVV) | Specialty clinic with full lab panels. | $200-450 / month | Patients integrating with broader optimization protocols |
| 503A pharmacy via clinician | Direct fill via established clinician relationship. | $60-180 / vial | Patients with established prescription managing ongoing cost |
How CJC-1295 no DAC (Modified GRF 1-29) samples actually work
Why this variant exists alongside sermorelin
Sermorelin and CJC-1295 no DAC are both 29-30 amino acid GHRH analogs that produce pulse-pattern GH release with daily dosing. The CJC-1295 no DAC variant has four amino acid substitutions that improve resistance to dipeptidyl peptidase-IV degradation, giving it slightly longer in-vivo activity than sermorelin. In clinical practice the difference rarely matters — both produce similar IGF-1 responses.
Pulse-pattern vs sustained elevation
The structural choice on the GHRH side of the protocol is between pulse-pattern (sermorelin, CJC-1295 no DAC) and sustained elevation (CJC-1295 with DAC). Pulse-pattern more closely resembles natural physiology and avoids the theoretical concern of suppressing endogenous GH production through sustained background elevation. Most clinicians who specialize in peptide therapy default to pulse-pattern unless there's a specific reason to choose sustained elevation.
Why the GHRP pairing is universal
Every clinical-track GHRH protocol — sermorelin, CJC-1295 no DAC, CJC-1295 with DAC — pairs with a GHRP, almost always ipamorelin. The GHRH provides the release signal; the GHRP amplifies the pituitary's response. Solo GHRH produces a meaningful but smaller GH pulse than the combo.
CJC-1295 no DAC and sermorelin are functionally interchangeable in most clinical contexts. The choice is usually clinician preference and pharmacy availability — not a meaningful pharmacological distinction.
CJC-1295 no DAC (Modified GRF 1-29) cost in 2026: every legitimate price path
What you'll actually pay depends on insurance, the path you take, and whether you stay on the brand-name drug. Here's the real money:
| Path | First month | Ongoing | Notes |
|---|---|---|---|
| Telehealth combo bundle | $99-149 | $99-229 / mo | CJC-1295 no DAC + ipamorelin combo pricing. |
| Specialty peptide clinic | $300-600 | $200-450 / mo | Full labs + protocol customization. |
| 503A pharmacy via clinician | $160-320 | $60-180 / vial | Lowest ongoing cost. |
What to expect on CJC-1295 no DAC (Modified GRF 1-29): your first weeks
Baseline labs (IGF-1, fasting metabolic) before initiating.
Subjective effects (sleep, recovery) often shift in the first 4-8 weeks.
IGF-1 response visible in 8-12 week labs.
Clinical evidence behind CJC-1295 no DAC (Modified GRF 1-29)
Pharmacokinetics of Modified GRF (1-29) are well-characterized in the literature. Clinical outcomes parallel sermorelin in most published comparisons. Regulatory status pending PCAC review.
CJC-1295 no DAC (Modified GRF 1-29)side effects & who shouldn't take it
This is not medical advice. Discuss every medication decision with a licensed clinician who knows your full medical history.
Common side effects
- •Injection-site soreness or transient itching
- •Mild flushing post-dose
- •Headache during first week
- •Vivid dreams from GH pulse
- •Carpal-tunnel-like symptoms at higher doses (uncommon)
Who shouldn't take CJC-1295 no DAC (Modified GRF 1-29)
- •Patients with active malignancy
- •Pregnancy or breastfeeding
- •Untreated diabetic retinopathy
- •Patients on corticosteroids that would blunt the GH response
Eligibility for CJC-1295 no DAC (Modified GRF 1-29)
- •Adult age 21+
- •Baseline IGF-1 and fasting metabolic panel in hand
- •Willingness to maintain quarterly lab monitoring
- •No active malignancy or untreated diabetic retinopathy
CJC-1295 no DAC (Modified GRF 1-29) samples: frequently asked
What's the difference between CJC-1295 no DAC and Modified GRF 1-29?
They are the same molecule. 'CJC-1295 no DAC' and 'Modified GRF (1-29)' are interchangeable names for the 30-amino-acid GHRH analog without the Drug Affinity Complex modification.
Sermorelin or CJC-1295 no DAC — which should I choose?
In most clinical contexts they are interchangeable. CJC-1295 no DAC has slightly longer in-vivo activity due to the DPP-IV-resistant amino acid substitutions. Choice is typically clinician preference and pharmacy availability rather than a meaningful clinical distinction.
Is CJC-1295 no DAC cheaper than CJC-1295 with DAC?
Per vial, yes — typically 30-60% cheaper. Per month, it's similar because the no-DAC variant requires daily dosing while the DAC variant is weekly. The cost-per-month tradeoff is roughly a wash; the choice is dosing-convenience vs pulse-pattern preference.
Why is 'no DAC' sometimes called 'Mod GRF'?
Historical naming convention. The molecule was originally referred to in the literature as Modified GRF (1-29) or Mod GRF. The 'CJC-1295 no DAC' designation came later, after the DAC variant was developed and a naming convention was needed to distinguish them.
Can I switch between CJC-1295 no DAC and sermorelin?
Yes, with clinician oversight. Switching is straightforward because the molecules act on the same receptor with similar pharmacokinetics. Reasons to switch usually include pharmacy availability, cost, or clinician protocol preference.